UnitedHealth's Turnaround Has a Number: 83.9%

For the past two years, UnitedHealth Group has been the most troubled stock in the Dow Jones Industrial Average. The murder of UnitedHealthcare CEO Brian Thompson in December 2024 triggered a national reckoning with the health insurance industry. Medical loss ratios climbed toward 90% as post-pandemic care utilization surged and high-cost specialty drugs strained the books. The company cut its profit outlook twice in 2025. Its stock fell more than 40% from its peak. And a new CEO, Stephen Hemsley - the architect of UnitedHealth's original rise - was brought back out of retirement to execute a turnaround that many analysts doubted was achievable on any reasonable timeline.

On Tuesday morning, UnitedHealth gave the market a number that suggests the turnaround is real. Its medical benefit ratio for the first quarter of 2026 came in at 83.9%. Analysts had expected 85.5%. A year ago, the same metric was 84.8%. At the worst point of the crisis in mid-2025, it had approached 90%. The improvement of nearly 160 basis points versus the prior year - and 160 basis points versus the consensus estimate - is the single most important data point in Tuesday's earnings report, and it is the reason the stock jumped roughly 8% in morning trading.

The Numbers Behind the Recovery

The headline figures were strong across the board. Revenue came in at $111.72 billion, above the $109.57 billion analyst consensus and up 2% from the prior-year quarter. Adjusted earnings per share hit $7.23, well above the $6.57 expected - a beat of more than 10%. GAAP net income was $6.28 billion, or $6.90 per share. Operating cash flow was $8.9 billion. The company raised its full-year 2026 adjusted EPS guidance to more than $18.25 per share, up from the prior outlook of more than $17.75 - a $0.50 increase that signals management's confidence that the first-quarter improvement is sustainable rather than a one-quarter anomaly.

Both of UnitedHealth's major business segments beat analyst revenue estimates. UnitedHealthcare, the insurance arm, and Optum, the health services and pharmacy benefit management business, both came in above expectations. Optum Health revenue was $24.1 billion, down 3% year over year as the company deliberately reduced its value-based care membership as part of the right-sizing strategy. That decline was expected and is part of the plan: Hemsley has been explicit that UnitedHealth is shrinking to grow, cutting unprofitable contracts and membership before rebuilding on a more sustainable cost structure.

What the MCR Improvement Actually Means

The medical benefit ratio is the most closely watched metric in health insurance. It measures the percentage of premium revenue that a company pays out in medical claims. A ratio of 83.9% means that for every dollar UnitedHealth collected in premiums, it paid out roughly 84 cents in medical costs and kept the rest to cover administrative expenses and generate profit. The lower the ratio, the more profitable the insurance business.

The improvement from 84.8% to 83.9% sounds modest in absolute terms, but at UnitedHealth's scale - the company covers more than 50 million people - each percentage point of MCR improvement translates into billions of dollars of operating income. The gap between the reported 83.9% and the expected 85.5% is even more significant: it means the company's medical cost management is running materially better than the market had priced in.

UnitedHealth attributed the improvement to three factors: strong management of medical costs, the release of previously set-aside reserves for unprofitable Optum contracts, and pricing discipline in its insurance products. The company was careful to note that medical costs remain consistently elevated - the underlying utilization pressures from post-pandemic catch-up care and GLP-1 drug costs have not disappeared. But the company's ability to price ahead of those costs, and to manage them more effectively through its Optum care delivery network, is showing up in the numbers in a way that was not visible a year ago.

The Medicare Advantage Tailwind

The timing of Tuesday's results is favorable in ways that go beyond the company's own execution. Just two weeks ago, the Trump administration finalized its 2027 payment rate increase for Medicare Advantage plans, and the final rate was substantially larger than the initial proposal. Medicare Advantage - the privately run version of Medicare that UnitedHealth dominates with roughly 8 million members - has been the primary source of the company's medical cost problems over the past two years. An influx of sicker-than-expected members, combined with inadequate payment rates, compressed margins severely. The larger-than-expected 2027 rate increase is a direct tailwind that will begin flowing through UnitedHealth's financials next year.

The company is also in the middle of a deliberate membership reduction in Medicare Advantage. It lost approximately 965,000 Medicare Advantage members in the first quarter as it exited unprofitable markets and tightened eligibility criteria. That is a painful short-term move - fewer members means less revenue - but it is the right strategic decision if the remaining membership is more profitable. The combination of a smaller, better-priced book of business and a more favorable payment rate environment in 2027 is the foundation of the bull case for UnitedHealth's recovery.

The GLP-1 Question

The most consequential unresolved issue in Tuesday's earnings call was UnitedHealth's stance on Medicare coverage of GLP-1 obesity drugs. Starting July 1, Medicare is expanding coverage for drugs like Wegovy and Zepbound, and insurers had until Monday to notify the federal government whether they would participate. UnitedHealth, as the largest Medicare Advantage provider, is critical to the program's viability.

Bobby Hunter, the head of UnitedHealth's government programs, was deliberately noncommittal on the call. "We'd like to find a path, yes, there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure," he said. "So, we're still working through that process internally and we look forward to continuing the dialogue with CMS." That language is carefully chosen. It signals that UnitedHealth has not committed to the program, that it has concerns about the financial structure, and that it is using its leverage as the dominant Medicare Advantage insurer to negotiate better terms before signing on.

The GLP-1 coverage question matters enormously for the broader healthcare sector. If UnitedHealth and other large insurers decline to participate, the Medicare obesity drug program could fail to reach the scale that Novo Nordisk and Eli Lilly are counting on. If they participate on terms that are financially sustainable, it could accelerate GLP-1 adoption among the Medicare population - the demographic with the highest rates of obesity-related conditions - and generate a new wave of demand for both drugs and the downstream healthcare services that follow weight loss treatment.

The Longer Road Back

One strong quarter does not complete a turnaround. UnitedHealth's stock is still well below its 2024 peak, and the company faces structural challenges that a single earnings beat cannot resolve. The reputational damage from the Thompson murder and the subsequent public backlash against prior authorization practices has not faded. The company is selling its UK Optum business and restructuring its care delivery operations in ways that will take years to fully execute. And the underlying cost pressures in the US healthcare system - aging population, specialty drug inflation, post-pandemic utilization - are not going away.

But Tuesday's results are a meaningful data point in the right direction. The MCR of 83.9% is the best the company has reported in several quarters. The guidance raise signals that management believes the improvement is durable. And the Medicare Advantage payment rate tailwind provides a structural backdrop that was absent during the worst of the crisis. Hemsley's turnaround plan is working faster than the market expected. The question now is whether the company can sustain this trajectory through the rest of 2026 - and whether the GLP-1 coverage decision, when it finally comes, adds to the recovery or complicates it.